Is your company trying to expand into “digiceuticals” or digital therapeutics? Are you looking to meet with investors distinguishing among the competing technologies and the therapeutic partners who might benefit from such apps? If so, you are invited to join us at the BIO Investor Forum, taking place October 17-18 in San Francisco. As part of this year’s program, Jeffrey Abraham of Akili Interactive, Christopher D.T. Guiffre of Pear Therapeutics, and David Klein of Click Therapeutics will be leading a panel discussion focused on Digiceuticals as a new class of FDA-approved therapeutics and the investment and partnering opportunities this presents.
Within the past year, the FDA has launched a provider pre-certification program as a pilot to manage the expansion of “digiceuticals” or digital therapeutics that produce clinical benefits for patients via interaction with a software application or mobile app. The panel will explore how the innovative regulatory approach seeks to provide discipline around clinical utility with the iterative improvements enabled by software versus standard manufactured medicines. The conversation will also cover the near-instant worldwide distribution platforms of mobile apps and how the technology enables fundamental changes in managing interactions with patients to understand and treat disease, with clear collaboration benefits between biopharma and digital therapy providers.